NURIX THERAPEUTICS, INC. Revenue
NURIX THERAPEUTICS, INC. (NRIX) reported Revenue of $9.04 million for the 3-month period ending 2026-05-31, per its 10-Q filed 2026-07-09.
Financial Statements › Income Statement
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax · last filed 2026-07-09
- NURIX THERAPEUTICS, INC. revenue from contract with customer, excluding assessed tax for the quarter ending 2026-05-31 was $9.04M, a 79.47% decline year-over-year.
- NURIX THERAPEUTICS, INC. revenue from contract with customer, excluding assessed tax for the quarter ending 2026-02-28 was $6.25M, a 66.12% decline year-over-year.
- NURIX THERAPEUTICS, INC. revenue from contract with customer, excluding assessed tax for the quarter ending 2025-11-30 was $13.58M, a 2.21% increase year-over-year.
- NURIX THERAPEUTICS, INC. revenue from contract with customer, excluding assessed tax for the quarter ending 2025-08-31 was $7.89M, a 37.29% decline year-over-year.
- NURIX THERAPEUTICS, INC. revenue from contract with customer, excluding assessed tax for fiscal 2025 was $83.98M, a 53.95% increase from fiscal 2024.
- NURIX THERAPEUTICS, INC. revenue from contract with customer, excluding assessed tax for fiscal 2024 was $54.55M, a 29.15% decline from fiscal 2023.
- NURIX THERAPEUTICS, INC. revenue from contract with customer, excluding assessed tax for fiscal 2023 was $76.99M, a 99.31% increase from fiscal 2022.
- NURIX THERAPEUTICS, INC. revenue from contract with customer, excluding assessed tax for fiscal 2022 was $38.63M.
| Period end | Revenue from Contract with Customer, Excluding Assessed Tax 3 month | Revenue from Contract with Customer, Excluding Assessed Tax 6 month | Revenue from Contract with Customer, Excluding Assessed Tax 9 month | Revenue from Contract with Customer, Excluding Assessed Tax 12 month |
|---|---|---|---|---|
| 2026-05-31 | $9.04M 10-Q · filed 2026-07-09 | $15.29M 10-Q · filed 2026-07-09 | $28.87M derived: sum of 3 quarters · filed 2026-07-09 | $36.77M derived: sum of 4 quarters · filed 2026-07-09 |
| 2026-02-28 | $6.25M 10-Q · filed 2026-04-08 | $19.83M derived: sum of 2 quarters · filed 2026-04-08 | $27.72M derived: sum of 3 quarters · filed 2026-04-08 | $71.78M derived: sum of 4 quarters · filed 2026-07-09 |
| 2025-11-30 | $13.58M derived: 10-K 12 month − 10-Q 9 month · filed 2026-01-28 | $21.47M derived: sum of 2 quarters · filed 2026-01-28 | $65.53M derived: sum of 3 quarters · filed 2026-07-09 | $83.98M 10-K · filed 2026-01-28 |
| 2025-08-31 | $7.89M 10-Q · filed 2025-10-09 | $51.95M derived: sum of 2 quarters · filed 2026-07-09 | $70.40M 10-Q · filed 2025-10-09 | $83.69M derived: sum of 4 quarters · filed 2026-07-09 |
| 2025-05-31 | $44.06M 10-Q · filed 2026-07-09 | $62.51M 10-Q · filed 2026-07-09 | $75.79M derived: sum of 3 quarters · filed 2026-07-09 | $88.38M derived: sum of 4 quarters · filed 2026-07-09 |
| 2025-02-28 | $18.45M 10-Q · filed 2026-04-08 | $31.74M derived: sum of 2 quarters · filed 2026-04-08 | $44.33M derived: sum of 3 quarters · filed 2026-04-08 | $56.42M derived: sum of 4 quarters · filed 2026-04-08 |
| 2024-11-30 | $13.28M derived: 10-K 12 month − 10-Q 9 month · filed 2026-01-28 | $25.87M derived: sum of 2 quarters · filed 2026-01-28 | $37.96M derived: sum of 3 quarters · filed 2026-01-28 | $54.55M 10-K · filed 2026-01-28 |
| 2024-08-31 | $12.59M 10-Q · filed 2025-10-09 | $24.68M derived: sum of 2 quarters · filed 2025-10-09 | $41.27M 10-Q · filed 2025-10-09 | $56.42M derived: sum of 4 quarters · filed 2026-01-28 |
| 2024-05-31 | $12.09M 10-Q · filed 2025-07-09 | $28.68M 10-Q · filed 2025-07-09 | $43.84M derived: sum of 3 quarters · filed 2026-01-28 | $62.30M derived: sum of 4 quarters · filed 2026-01-28 |
| 2024-02-29 | $16.59M 10-Q · filed 2025-04-08 | $31.74M derived: sum of 2 quarters · filed 2026-01-28 | $50.21M derived: sum of 3 quarters · filed 2026-01-28 | $80.89M derived: sum of 4 quarters · filed 2026-01-28 |
| 2023-11-30 | $15.16M derived: 10-K 12 month − 10-Q 9 month · filed 2026-01-28 | $33.63M derived: sum of 2 quarters · filed 2026-01-28 | $64.30M derived: sum of 3 quarters · filed 2026-01-28 | $76.99M 10-K · filed 2026-01-28 |
| 2023-08-31 | $18.47M 10-Q · filed 2024-10-11 | $49.14M derived: sum of 2 quarters · filed 2024-10-11 | $61.83M 10-Q · filed 2024-10-11 | |
| 2023-05-31 | $30.68M 10-Q · filed 2024-07-11 | $43.36M 10-Q · filed 2024-07-11 | ||
| 2022-11-30 | $38.63M 10-K · filed 2025-01-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| SELLAS Life Sciences Group, Inc. (SLS) | United States | $2.420B | -91.87 |
| uniQure N.V. (QURE) | $2.416B | -4.93 | |
| Vera Therapeutics, Inc. (VERA) | United States | $2.402B | -7.67 |
| Harmony Biosciences Holdings, Inc. (HRMY) | United States | $2.399B | 11.67 |
| SUPERNUS PHARMACEUTICALS, INC. (SUPN) | United States | $2.517B | -24.63 |
| Immunome Inc. (IMNM) | United States | $2.538B | -9.45 |
| Disc Medicine, Inc. (IRON) | United States | $2.553B | -11.40 |
| Mineralys Therapeutics, Inc. (MLYS) | United States | $2.353B | -6.82 |
| Viridian Therapeutics, Inc.\DE (VRDN) | United States | $2.342B | -5.38 |
| MBX Biosciences, Inc. (MBX) | United States | $2.664B | -25.36 |